Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023)
Contineum Therapeutics' (CTNM) quarterly Long-Term Debt Repayments came in at $3.1 million in Q2 2023, up 400.0% quarter-over-quarter from $625000.0 in Q1 2023.
Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023) Analysis & Trends
Contineum Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $3.1 million for Q2 2023.
- On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $3.1 million in Q2 2023; TTM through Mar 2024 was $3.1 million, a N/A change from a year earlier, with the FY2023 full-year figure at $3.8 million, changed N/A from the prior year.
- Long-Term Debt Repayments advanced to $3.1 million in Q2 2023 per CTNM's latest filing, from $625000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $3.1 million in Q2 2023 and bottomed at $625000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Contineum Therapeutics | 536.56 Mn | 536.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 3.13 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 625,000.00 |
| Mar 31, 2023 | 625,000.00 |